number
patient
receiv
hematopoiet
stem
cell
transplant
hsct
rapidli
rise
worldwid
despit
substanti
improv
peritranspl
care
pulmonari
complic
result
respiratori
failur
remain
major
contributor
morbid
mortal
posttranspl
period
repres
major
barrier
overal
success
hsct
infecti
complic
includ
pneumonia
due
bacteria
virus
fungi
commonli
occur
neutropenia
earli
posttranspl
period
noninfecti
complic
includ
idiopath
pneumonia
syndrom
periengraft
respiratori
distress
syndrom
diffus
alveolar
hemorrhag
pulmonari
venoocclus
diseas
delay
pulmonari
toxic
syndrom
cryptogen
organ
pneumonia
bronchiol
obliteran
syndrom
posttranspl
lymphoprolif
disord
complic
distinct
clinic
featur
risk
factor
occur
differ
time
follow
transplant
contribut
morbid
mortal
hematopoiet
stem
cell
transplant
hsct
creasingli
util
worldwid
definit
treatment
hematolog
malign
condit
transplant
perform
annual
hsct
patient
undergo
high
dose
condit
chemotherapi
andor
radiat
therapi
view
erad
immun
system
along
residu
malign
cell
stem
cell
collect
beforehand
administ
condit
complet
reconstitut
immun
system
hsct
may
autolog
donor
stem
cell
patient
allogen
donor
stem
cell
appropri
match
donor
posttransplant
period
tempor
sepa
rate
three
phase
repres
dynam
individu
spectrum
risk
figur
first
pha
se
pancytopen
phase
immedi
follow
transplant
typic
last
follow
hsct
autolog
transplant
recipi
typic
engraft
allogen
sever
peritranspl
factor
peripher
stem
cell
harvest
use
granulocyt
stimul
factor
posttranspl
period
promot
earlier
marrow
recoveri
second
phase
occur
neutrophil
engraft
absolut
neutrophil
count
consist
exce
cell
per
mm
second
phase
typic
last
first
day
follow
transplant
third
phase
consid
late
complic
transplant
occur
often
allogen
transplant
graftversushost
effect
pulmonari
manifest
pulmonari
complic
respiratori
failur
common
occur
twothird
hsct
recipi
associ
signific
morbid
mortal
pulmonari
complic
character
phase
posttranspl
period
like
occur
figur
purpos
minireview
highlight
infecti
noninfecti
sourc
respiratori
failur
hsct
recipi
respiratori
failur
follow
hsct
present
spectrum
wieruszewski
pm
et
al
respiratori
failur
hsct
sever
sever
aspect
clinic
present
provid
clue
possibl
etiolog
acut
versu
subacut
earli
posthsct
late
posthsct
diffus
versu
focal
substanti
number
patient
sever
end
spectrum
present
acut
hypoxem
respiratori
failur
diffus
pulmonari
infiltr
meet
criteria
acut
respiratori
distress
syn
drome
ard
underli
etiolog
often
known
time
present
principl
ard
manag
prevent
equal
valid
popul
specif
includ
lungprotect
mechan
ventil
low
tidal
volum
strategi
appropri
recruit
use
neuromuscular
block
ade
appropri
addit
focu
prevent
iatrogen
secondhit
judici
fluid
blood
product
administr
aspir
precaut
earli
focu
mobil
ventil
liber
lung
injuri
prevent
guidelin
conceptu
checklist
lung
injuri
prevent
recent
implement
part
ard
prevent
clinic
trial
patient
preexist
pulmonari
diseas
suscept
pulmonari
complic
particularli
receiv
high
dose
radiat
lung
part
condit
program
concurr
patient
evalu
possibl
etiolog
present
divid
broadli
infecti
noninfecti
caus
infecti
pulmonari
complic
common
immedi
posttranspl
period
neutropenia
recipi
allogen
hsct
typic
prone
infecti
pulmonari
complic
due
longer
period
neutropenia
need
immunosuppress
medic
administr
prevent
graftversushost
diseas
routin
infecti
prophylaxi
neutro
penia
dramat
reduc
burden
infecti
complic
howev
breakthrough
infect
occur
varieti
caus
organ
vari
depend
patient
transplant
characterist
time
elaps
follow
transplant
figur
bacteri
pneumonia
commonli
occur
earli
transplant
period
risk
bacteri
pneumonia
allotranspl
greater
myeloabl
oppos
nonmyeloabl
reduc
intens
condit
use
patient
graftversushost
diseas
delay
engraft
prolong
period
neutro
penia
indwel
devic
earli
posttranspl
period
gramneg
organ
pseudomona
aeruginosa
klebsiella
pneumonia
suspect
wherea
encapsul
organ
concern
late
hsct
patient
develop
hypoxem
respiratori
failur
new
pulmonari
infil
trate
follow
hsct
infect
typic
presum
approach
reason
given
substanti
mor
taliti
associ
delay
antimicrobi
therapi
immunocompromis
patient
ideal
microbiolog
sampl
bronchoalveolar
lavag
bal
prefer
although
risk
benefit
invas
sampl
need
individu
assess
patient
antibacteri
infecti
prophylaxi
pneumonia
suspect
antibacteri
agent
broaden
cover
noso
comial
pathogen
certain
infecti
syndrom
worthi
addi
tional
discuss
encapsul
bacteria
particularli
streptococcu
pneumonia
suspect
later
follow
hsct
commonli
mo
invas
pneumococc
diseas
report
time
preval
hsct
recipi
compar
gener
popul
case
bacteremia
nocardia
pneumonia
occur
late
posttranspl
period
usual
mo
nocardi
infect
uncommon
hsct
suspect
nonrespond
initi
antimicrobi
therapi
sulfamethoxazoletrimethoprim
treatment
choic
respons
therapi
typic
robust
routin
use
sulfamethoxazoletrimethoprim
pneumocysti
prophylaxi
adequ
protect
nocardiosi
mycobacteri
pneumonia
rare
occur
late
posttranspl
period
typic
present
one
year
hsct
incid
mycobacteria
tuberculosi
among
hsct
recipi
higher
endem
area
receiv
allogen
graft
present
manag
infect
nontubercul
mycobacteria
similar
gener
popul
herp
simplex
viru
hsv
infect
rel
uncom
mon
follow
hsct
due
routin
infecti
prophylaxi
acyclovir
hsv
pneumonia
typic
occur
earli
posttranspl
period
result
latent
reactiv
figur
allotranspl
receiv
graft
seroposit
donor
graftversushost
diseas
increas
risk
hsv
diagnosi
hsv
pneumonia
challeng
sinc
lowgrad
hsv
reactiv
viral
shed
uncommon
critic
ill
qualit
polymeras
chain
reaction
pcr
bal
sampl
exquisit
sensit
cytomegaloviru
cmv
pneumonia
occur
allotranspl
typic
present
en
graftment
around
mo
figur
occur
commonli
seroposit
allograft
recipi
receiv
seroneg
transplant
pulmonari
imag
find
nonspecif
typic
bilater
diffus
alveolar
nodular
opac
bal
fluid
analyz
confirm
presenc
cmv
pcr
common
shell
assay
viral
cultur
low
grade
cmv
shed
uncommon
critic
ill
nt
necessarili
indic
pneumon
definit
diagnosi
requir
demonstr
tissu
involv
lung
biopsi
rare
perform
presenc
cmv
bal
compat
clinic
radiograph
pictur
support
evid
widespread
cmv
reactiv
usual
need
initi
treatment
elev
escal
quantit
serum
pcr
evid
cmv
involv
organ
eg
gut
cn
support
system
cmv
infect
ganciclovir
treatment
choic
invas
cmv
diseas
though
treatment
limit
leukopenia
particularli
problemat
among
hsct
popul
epidemiolog
posthsct
cmv
pneumon
may
chang
novel
cmv
prophylact
agent
routin
administ
communityacquir
respiratori
virus
carv
includ
influenza
viru
parainfluenza
viru
respiratori
syncyti
viru
rsv
adenoviru
rhinoviru
enteroviru
coronaviru
occur
entir
post
transplant
period
figur
diagnosi
occur
commonli
nasal
pcramplif
assay
bal
rsv
commonli
isol
carv
estim
recov
third
patient
undergo
hsct
first
three
year
addit
hypoxia
patient
typic
present
fever
product
cough
dyspnea
chest
imag
find
includ
diffus
patchi
alveolar
opac
rsv
hsct
popul
highli
morbid
mortal
rate
port
beyond
support
care
specif
therapi
shown
consist
benefit
given
high
mortal
rate
hsct
recipi
high
rsv
titer
immun
globulin
aerosol
ribavirin
may
consid
pulmonari
aspergillosi
effect
twothird
hsct
recipi
although
incid
declin
routin
antiaspergillu
prophylaxi
neutropenia
effect
treatment
graftversushost
diseas
pulmonari
aspergillosi
report
upward
hsct
recipi
risk
factor
includ
allogen
transplant
unrel
donor
prolong
neu
tropenia
immunosuppress
use
graftversushost
diseas
cmv
infect
common
find
radiolog
includ
pulmonari
nodul
without
halo
sign
ground
glass
opac
air
crescent
sign
necrot
tissu
advanc
case
hemoptysi
present
typic
associ
poor
prognosi
diagnosi
confirm
aspergillu
specif
pcr
aspergillu
sp
antigen
bal
mono
therapi
isavuconazol
voriconazol
prefer
firstlin
treatment
therapeut
drug
monitor
util
ensur
adequaci
dose
se
vere
case
refractori
medic
therapi
recurr
hemoptysi
may
consid
surgic
evalu
though
lung
resect
highli
morbid
associ
signific
mortal
popul
incid
pneumocysti
jirovecii
pneumonia
pcp
margin
declin
recent
year
use
prophylaxi
increas
howev
limit
guidanc
consensu
patient
outsid
hivposit
individu
receiv
prophylaxi
therefor
pcp
remain
highli
relev
hsct
recipi
institut
routin
implement
prophylaxi
engraft
first
longer
patient
immunosuppress
graftversu
host
diseas
pcp
occur
late
hsct
present
acut
onset
sever
respiratori
failur
diagnosi
confirm
identif
pneumocysti
organ
respiratori
sampl
pcr
fungal
smear
sulfamethoxazol
trimethoprim
treatment
choic
highli
effect
kill
pneumocysti
sp
patient
pcp
typic
die
due
refractori
hypoxemia
sever
respiratori
failur
corticosteroid
fail
demonstr
benefit
outsid
hiv
popul
nonetheless
adjunct
corticosteroid
typic
administ
individu
hsct
develop
pcp
noninfecti
respiratori
failur
syndrom
common
throughout
entir
posthsct
period
stand
remain
incomplet
risk
syndrom
vari
base
transplant
type
varieti
modifi
nonmodifi
transplant
patient
characterist
addit
key
distinguish
clinic
criteria
noninfecti
complic
categor
occur
tempor
follow
hsct
figur
often
infect
rule
time
initi
present
concurr
treat
given
substanti
mortal
associ
delay
antimicrobi
administr
periengraft
respiratori
distress
syndrom
perd
pulmonari
subset
engraft
syn
drome
system
capillari
leak
disord
develop
around
time
immun
system
reconstitut
earli
autolog
hsct
figur
perd
defin
hypoxem
respiratori
failur
bilater
pulmonari
infiltr
occur
surround
neutrophil
engraft
fulli
explain
cardiac
dysfunct
infect
focus
studi
perd
patient
found
incid
nearli
autotranspl
casefat
rate
excess
nearli
two
decad
ago
substanti
reduc
current
era
risk
factor
clude
femal
gender
blood
product
administr
rapid
engraft
hsct
poem
syndrom
recent
found
radiograph
chang
consist
lung
injuri
preced
neutrophil
engraft
may
aid
earli
identif
syndrom
treatment
consist
short
cours
high
dose
corticosteroid
commonli
mgkg
methylprednisolon
twice
daili
follow
rapid
taper
respons
typic
prompt
improv
oxygen
within
h
steroid
initi
diffus
alveolar
hemorrhag
dah
syndrom
cha
racter
diffus
bilater
pulmonari
infiltr
progress
bloodi
return
bal
presenc
hemosiderinladen
macrophag
alveolar
lavag
fluid
hemoptysi
seen
often
absent
dah
mainli
occur
earli
post
transplant
period
figur
dah
occur
hsct
recipi
highli
morbid
report
mortal
rate
high
risk
factor
includ
age
year
higher
intens
condit
therapi
total
bodi
irradi
hsct
acut
leukemia
myelo
dysplast
syndrom
understand
dah
follow
hsct
limit
case
alveolar
hemorrhag
occur
thrombocytopen
period
follow
transplant
mani
case
occur
platelet
count
adequ
also
dah
may
occur
set
ard
pneumonia
dah
case
occur
absenc
treatment
dah
consist
highdos
corticosteroid
commonli
mg
methylprednisolon
per
day
one
studi
show
improv
surviv
patient
treat
antifibrinolyt
amino
caproic
acid
subsequ
larger
studi
fail
show
benefit
even
presenc
thrombo
cytopenia
platelet
transfus
affect
morbid
mortal
dah
idiopath
pneumonia
syndrom
ip
umbrella
term
widespread
alveolar
injuri
occur
absenc
cardiac
renal
dysfunct
iatrogenicinduc
circulatori
overload
infect
symptom
consist
ard
pulmonari
imag
typic
reveal
diffus
bilater
pulmonari
infiltr
mani
similar
overlap
clinic
present
ip
noninfecti
complic
discuss
review
condit
key
distinguish
featur
therefor
discuss
separ
ip
effect
hsct
recipi
allotranspl
typic
occur
earli
posttranspl
period
figur
mortal
high
even
greater
requir
respiratori
support
mechan
ventil
risk
factor
includ
higher
intens
condit
therapi
radiat
administr
allogen
transplant
age
presenc
graftversushost
diseas
treatment
ip
controversi
therapi
shown
favor
outcom
corticosteroid
may
administ
though
studi
shown
nefit
other
given
higher
dose
mgkg
per
day
prednisolon
equival
shown
better
lower
dose
mgkg
per
day
less
prednisolon
equival
potenti
carri
greater
risk
advers
effect
ongo
interest
tumor
necrosi
factor
tnf
inhibit
due
observ
patient
ip
cyto
kinerich
bal
fluid
preliminari
retrospect
studi
shown
promis
increas
respons
rate
improv
overal
surviv
inhibitor
etanercept
ad
corticosteroid
therapi
though
find
replic
random
control
trial
design
appli
studi
need
better
phenotyp
ip
truli
repres
whether
therapi
effect
pulmonari
venoocclus
diseas
pvod
rare
com
plicat
hsct
high
associ
mortal
typic
occur
late
hsct
figur
pvod
suspect
progress
dyspneic
evid
pulmonari
hypertens
absenc
left
heart
failur
imag
suggest
pulmonari
edema
pvod
may
occur
absenc
therefor
diagnosi
must
confirm
pre
senc
fibrou
intim
prolifer
pulmonari
venul
open
surgic
lung
biopsi
due
low
incid
pvod
follow
hsct
inabl
studi
larg
number
case
risk
fac
tor
extrapol
nonhsct
popul
includ
viral
infect
genet
predisposit
autoimmun
disord
toxic
insult
endothelia
context
hsct
insult
includ
condit
chemotherapi
bleomycin
mitomycin
carmustin
irradi
despit
use
primari
pul
monari
hypertens
pulmonari
vasodil
may
detriment
pvod
avoid
dilat
pulmonari
arteri
vasculatur
set
fix
venou
resist
may
precipit
pulmonari
edema
worsen
respiratori
statu
corticosteroid
may
administ
though
data
spars
overal
prog
nosi
poor
patient
may
consid
evalu
lung
transplant
elig
delay
pulmonari
toxic
syndrom
dpt
constel
interstiti
pneumon
fibrosi
occur
ring
late
transplant
period
present
year
hsct
characterist
dpt
appear
confin
patient
receiv
highdos
chemotherapi
follow
autolog
stem
cell
rescu
breast
cer
accordingli
incid
dpt
specif
popul
report
high
symptom
nonspecif
includ
dyspnea
fever
non
product
cough
similarli
chest
imag
reveal
bilater
interstiti
infiltr
ground
glass
opac
dpt
occur
late
follow
hsct
present
sever
year
follow
transplant
figur
syndrom
highli
respons
corticosteroid
typic
asso
ciat
favor
outcom
cryptogen
organ
pneumonia
cop
interstiti
airspac
diseas
symptom
mimick
classic
pneumonia
imag
find
includ
nodular
lesion
ground
glass
attenu
patchi
peribronchovascular
peripher
bandlik
consolid
distribut
biopsi
reveal
chronic
alveolar
inflamm
exten
sive
granul
alveolar
duct
small
airway
bronchoscopi
use
distinguish
cop
infecti
pneumonia
analysi
lavag
fluid
reveal
predo
minant
lymphocytosi
previous
refer
bron
chioliti
obliteransorgan
pneumonia
cop
distinct
entiti
bronchiol
obliteran
syndrom
bo
discuss
separ
confus
cop
occur
hsct
recipi
typic
present
late
follow
transplant
figur
risk
factor
includ
cyclophosphamid
condit
total
bodi
irradi
male
allotranspl
femal
cell
donor
presenc
graftversushost
diseas
hsct
leukemia
gener
cop
respons
corti
costeroid
therapi
typic
regimen
includ
mgkg
prednison
daili
extend
taper
mo
case
fatal
rate
report
usual
due
respiratori
failur
set
relaps
steroid
refractori
diseas
bo
slow
progress
small
airway
obstruct
believ
consequ
graftversushost
di
eas
bo
classic
manifest
month
year
abrupt
decompens
sever
respiratori
failur
uncommon
histolog
reveal
intra
lumin
fibrosi
howev
yield
transbronchi
biopsi
highli
depend
diseas
presenc
area
sampl
open
surgic
biopsi
high
risk
popul
therefor
acut
set
diagnosi
establish
basi
reduc
expiratori
flow
obstruct
airflow
radiolog
find
includ
hyperinfl
air
trap
mosaic
pattern
att
nuation
incid
bo
estim
like
associ
presenc
chronic
graftversushost
diseas
risk
factor
includ
elder
age
reduc
expiratori
capac
pretran
plantat
unrel
graft
donor
irradi
viral
infect
posthsct
highdos
corticosteroid
administ
week
month
mainstay
treatment
though
respons
rate
poor
bo
irrevers
mortal
rate
high
despit
extens
extrapol
use
solid
organ
transplant
patient
macrolid
shown
worsen
airflow
declinefre
surviv
hsct
recipi
therapi
inconclus
util
includ
inhal
corticosteroid
intraven
immun
globulin
hibitor
cyclosporin
tacrolimu
extracorpor
photophoresi
promis
therapi
increas
evid
suggest
potenti
benefit
lung
tran
plantat
advanc
bo
report
posttranspl
lymphoprolif
disord
ptld
rare
form
malign
secondari
epstein
barr
viru
ebv
infect
b
lymphocyt
occur
first
six
month
follow
allotranspl
figur
risk
factor
includ
tcell
deplet
donor
hla
donor
mismatch
tcell
deplet
therapi
includ
antithymocyt
globulin
antibodi
cmv
antigen
addit
hypoxia
symptom
con
sistent
viral
ill
chest
imag
reveal
diffus
basal
subpleur
infiltr
definit
diagnosi
establish
ebvassoci
lymphoid
prolifer
demonstr
biopsi
treatment
includ
modul
tcell
deplet
immunosuppress
administr
rituximab
antib
cell
antibodi
preliminari
report
demonstr
promis
infus
ebvspecif
tcell
therapeut
ptld
though
other
demonstr
resist
therapi
respiratori
failur
due
infecti
noninfecti
complic
common
follow
hsct
associ
signific
mortal
especi
necessit
mechan
ventil
pulmonari
complic
differenti
key
distinguish
featur
timecours
follow
transplant
acut
ill
pa
tient
meet
ard
criteria
routin
use
bestpractic
lungprotect
strategi
recommend
even
underli
explan
respiratori
failur
identifi
